Only the patients with
a total PANSS score (the sum of Positive
and Negative subscale ) at the baseline
more or 40 were eligible for entering
the study in outpatient and inpatient
setting. The primary efficacy parameter
of treatment was the percent of
score difference between baseline andthe end of observational period on two
above - entioned PANSS subscales. The
difference was considered as significant
improvement if decrease from the baseline
was 20% or more. The secondary efficacy
parameter was subjective clinical
evaluation of efficacy with five possible
answers: very good, good, moderate,
not satisfactory, not possible to evaluate.
It was measured at the end of observational
period by the investigator